Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Malignant Melanoma (US)

Analysis of: FDA will weigh Evista's cancer-reducing benefits (www.usatoday.com)
The data from the STAR P-2 trial on tamoxifen vs. raloxifene show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease. This very large trial...
Analysis of: Phase II Study of IMC-A12 for Advanced Colorectal Cancer Has Commenced Patient Enrollment (www.pipelinereview.com)
IMC-A12 is a fully human IgG1Mab that is designed to specifically target the human insulin-like growth factor type 1 receptor, thereby inhibiting certain ligands known as insulin-like growth factors I and II from binding to and activating the receptor. This action blocks a signaling pathway that enhances...
Analysis of: Affymax(R) Announces Phase 3 Development Plan for Hematide(TM) (www.pipelinereview.com)
Hematide provides a novel mechanism to increase hemoglobin by binding to the epo receptor.   It is unclear yet if hematide lacks the similar safety issues of Aranesp, Procrit, and Epogen, and these studies will hopefully shed some light. The longer interval between doses (4 weeks) is attractive...
July 19, 2007
A dangerous spiral
Analysis of: AMA warns of threat to doctors' pay (pressherald.mainetoday.com)
Continuous cuts in physician reimbursement along with rising practice overhead cost are eventually going to cost our health system's quality, and loss of access for patients.
Analysis of: Antisoma announces further data from ASA404 ovarian cancer trial (www.pipelinereview.com)
New phase II data shows no benefit in time to progression, and likely signals no further investigation in this drug for ovarian cancer However, early data for NSCLC has been reported as promising, and, this could be a potential avenue of research and future market.
Analysis of: Northwest Bio gets Swiss approval for brain cancer vaccine UPDATE (money.cnn.com)
While the idea of a vaccine against cancer is elegant in theory and design, prior vaccine trials have been busts.    Anecdotal stories always generate promise, but until it's proven in a randomized fashion, I won't believe the hype.
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
Analysis of: Laser Hair Removal Enhanced With Eflornithine Cream (www.medscape.com)
I do not believe that Vaniqa will have a negative effect on Laser hair removal as its efficacy is only temporary. In fact we use it as an adjunct for patients with resistant areas. Its use may actually enhance the use of Laser devices as they offer permanence. The products use may be increasing as more...
Analysis of: Physicians Favor a DTC Moratorium More Strongly Than Consumers, though Both Groups Cite Public Safety as the Key Benefit, according to New TNS Healthcare Research (pharmalive.com)
As drug companies have had physicians cut back on drug rep visits, and have had less ability to influence in prescribing due to big pharma guidelines, they have set their eyes on a new target - the patient
Analysis of: Study Finds Many Injuries to Surgeons Go Unreported (www.nytimes.com)
While we have made great strides in reducing needle sticks through education and newer safety needles, accidents still happen.   Reporting of injuries is important, not only to identify reasons why people have these accidents (and to hopefully help them learn behaviors to minimized these...
Analysis of: Cerner Receives FDA Clearance for Cerner Bridge Transfusion Administration and Specimen Collections (www.genengnews.com)
Cerner has made large leaps in electronic charting.   The addition of this package to their suite builds additional safety into their system while allowing transfuions to be administered in a safe, paperless manner.

Previous Page : 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next111 to 120 of 159

Analytics


Generated at 2009-01-07T19:00:58.307